Fundamentals of Liver Disease- Hepatitis B
- Registration Closed
The Fundamentals of Liver Disease Hepatitis B unit currently does not offer CME, CE or MOC. This unit is available for viewing purposes only. A newly updated version will be available soon for credits or points. Check back for updates!
There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.
The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.
Key topic areas:
HBV: Epidemiology and Screening
Patient with positive Hepatitis B serologies
Natural history of HBV and identification of treatment candidates
Management of the Chronic HBV patient with co-morbid and other conditions
Antiviral treatment of the Patient with Chronic HBV
Prevention of HBV infection
Hepatitis B in the Pediatric Patient
COMPONENTS
Online:
7 online interactive, narrated modules 30 to 40 minutes in length
Pre- and post-test questions for each module
Original release date: April 10, 2014
Review date: July 1, 2017
Re-release date: December 1, 2017
Expiration date: November 30, 2019
Time to complete each module: 45-60 minutes
Copyright:
All faculty in this activity have given their permission for publication OR
©2017 AASLD
Contact Information
For questions on CE credit for this activity contact Certificate@AmedcoEmail.com
For questions on MOC/CME/CE content or the activity web site, contact education@aasld.org.
Naga P. Chalasani
Naga P. Chalasani, MD, FAASLD currently serves as David W. Crabb Professor of Medicine and Interim Chair of the Department of Medicine at Indiana University School of Medicine. He previously served as the Director of the Division of Gastroenterology and Hepatology at the same institution from 2007 to 2020. He completed his medical education in India and subsequently completed Internal Medicine Residency and Gastroenterology and Hepatology subspecialty training at Emory University in Atlanta. His research interests include CYP450 enzymes and liver disease and hepatic safety of xenobiotics. His research has been continuously funded by the National Institutes of Health since 1999. He is currently the PI for three U01 awards and an R01 award from the National Institutes of Health. He published over 300 original papers, 3 Practice Guidelines, 47 book chapters/review articles, 31 editorials/commentaries, 16 symposium proceedings, and more than 500 abstracts. He is the lead author for the AASLD Practice Guideline on the Diagnosis and Management of Nonalcoholic Fatty Liver Disease and is the lead author on the ACG Practice Guideline on the Diagnosis and Management of Drug Induced Liver Injury. He is an elected member of the American Society of Clinical Investigation (ASCI) and the American Association of Physicians (AAP).
Tram T. Tran
Tram T. Tran, MD, FAASLD is the Medical Director of Liver Transplantation at Cedars-Sinai Medical Center and Professor of Medicine at Geffen UCLA School of Medicine. Dr. Tran has broad research interests in the areas of viral hepatitis B and C, liver disease in pregnancy and liver transplantation. She is an internationally recognized expert and NIH-funded researcher in the field of chronic hepatitis B, and is active in patient and community advocacy on hepatitis B prevention and treatment. She has authored and co-authored numerous abstracts, papers and chapters in these fields and published in journals.
Mark W. Russo
Mark W. Russo, MD, MPH, FAASLD is Medical Director of Liver Transplantation, Chief, Division of Hepatology, and Clinical Professor of Medicine at Carolinas Medical Center-Atrium Health. At the American Association for the Study of Liver Diseases, Dr. Russo is Chair of the Maintenance of Certification Committee, member of the Nominating Committee, co-director of the 2020 AASLD Transplant Hepatology Board Review course, and member of a working group planning for the future hepatology workforce. He is an Associate Editor for the American Journal of Gastroenterology and serves on the editorial board of Expert Reviews in Gastroenterology and Hepatology and the Journal of Clinical Medicine. He has more than 100 peer-reviewed publications and editor of the textbook Diagnosis and Management of Autoimmune Hepatitis.
Marion G. Peters
Marion G. Peters, MBBS, MD, FAASLD is an Emeritus Professor of Medicine at the University of California at San Francisco and Adjunct Professor of Medicine at Northwestern University, Chicago. She is a hepatologist with a particular interest in viral hepatitis in complicated clinical settings, patients with co-morbid conditions including alcoholism and HIV infection. She led the NIH AIDS Clinical Trials Group (ACTG) Hepatitis Transformative Science Group (TSG) for 4 years where she championed young investigators to be chairs of new trials in Hep TSG. She is the Protocol Facilitator for ACTG Hepatitis TSG HBV-related studies, focusing on the development of US and international studies for new drugs for patients with HBV, with and without HIV. She is currently a team member or co-chair of 4 ACTG hepatitis trials. She is also a member of the HEP TSG steering committee.
Dr. Peters serves on the scientific Advisory Board of International Antiviral Society USA, HEP DART and is a senior advisor to International Coalition to Eliminate HBV. She is an editor for the Journal of Antimicrobial Chemotherapy. She has trained fellows, house staff and medical students in clinical and translational research, many of whom have gone on to faculty positions focusing on liver disease. She has mentored faculty and fellows in her institution, nationally and internationally. She is particularly focused on mentoring women in medicine. She has numerous publications on viral hepatitis with and without HIV coinfection in peer-reviewed journals with multiple collaborators.
Anna S. Lok
Lorraine Pelosof
Lorraine Pelosof, MD grew up in Dallas and graduated from The University of Texas at Austin. She completed her MD and her PhD in Molecular and Cell Biology at Washington University in St. Louis and then completed her Internal Medicine Residency at The University of Texas Southwestern Medical Center. Following residency, she did her fellowship training in Medical Oncology at Johns Hopkins where her research focused on DNA promoter methylation in gastrointestinal tumors. After serving as an Assistant Professor in the Division of Hematology/Oncology at UT Southwestern, she moved back to Maryland where she is a Medical Officer on the GI oncology team in the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration.
Maureen M. Jonas
Maureen M. Jonas, MD, FAASLD is the Director of the Center for Childhood Liver Disease in the Division of Gastroenterology, Hepatology and Nutrition at Boston Children’s Hospital, and Professor of Pediatrics at Harvard Medical School. Her area of expertise is Pediatric Hepatology and Liver Transplantation, with a special emphasis on viral hepatitis in children. She is the author of a number studies of therapies for pediatric viral hepatitis.
Dr. Jonas has served on several AASLD committees, including the Practice Guidelines Committee, Ethics Committee and Nominating Committee. She chaired several symposia sponsored by AASLD and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition at AASLD annual meetings. She has served as abstract reviewer for AASLD meetings, and ad hoc reviewer for Hepatology. Jonas established the Pediatric Transplant Hepatology training Program at Boston Children’s Hospital and served as its director until 2016. She was the Medical Director of the Liver Transplant Service at BCH from 1991 through 2014. As an active educator, she has mentored numerous pediatric gastroenterology and hepatology fellows, as well as junior faculty, over the last 30 years. She currently serves on the Transplant Hepatology Examination Committee for the American Board of Pediatrics. She has been the lead Principal Investigator for many multinational pediatric viral hepatitis trials and has lectured extensively on this topic around the country and around the world.
Key:
Complete
Next
Failed
Available
LockedLearning Objective:
• Identify patients with liver disease
• Apply diagnostic tests appropriately
• Discuss important counseling
• Recognize treatment/referral priorities
• Identify first line therapies for different liver diseases
• Refer to specialist in a timely and appropriate fashion
This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.
CME
Accreditation Statement
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
AASLD designates this enduring activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse
Amedco is accredited as a provider of continuin nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and AASLD. Maximum of 3.5 contact hours.
Maintenance of Certification (MOC) Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
How to Earn/Claim MOC
• For each module that you wish to claim MOC points for you must:
o Complete the pre-test
o Review/watch the slides in the presentation
o Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)
o Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)
• AASLD submits MOC points on behalf of its learners to ABIM once a month between 15th-20th. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.
• MOC points are available for ABIM board certified physicians only.
DISCLOSURE OF CONFLICTS OF INTEREST
AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
The organizers and faculty have reported the following disclosures:
Marc Ghany, MD
Faculty
Nothing to disclose
Tram Tran, MD
Faculty
Grant/Research Support: Bristol-Myers Squibb, Gilead; Consulting: Bristol-Myers Squibb, Gilead
Advisory Committee or Review Panels: Bristol-Myers Squibb, Gilead
Marion Peters, MD
Faculty
Employment (Spouse): Genentech Research and Development (subsidiary of Roche)
Anna S.F. Lok, MD
Faculty
Grant/Research Support: BMS and Gilead
Brian McMahon, MD, FAASLD
Faculty
Grant/Research Support: Gilead Sciences- grant received by department at institution and not directly.
Maureen Jonas, MD
FacultyAdvisory Committee or Review Panels: Served as chair of DSMB for Gilead
Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Roche, Echosens (equipment only)
Consulting: AbbVie
Lauren Beste, MD
Organizer
Nothing to disclose
Michael Fried, MD, FAASLD
Organizer, Faculty
Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and NIH
Scientific Consultant: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and TARGET PharmaSolutions
Guadalupe Garcia-Tsao, MD
Organizer
Advisory Committee: Abbvie, Fibrogen
Leslie Hayes, MD
Organizer
Nothing to disclose
Patrick Horne, MSN, ARNP, FNP-BC
Organizer
Consulting: Gilead Sciences, Bristol-Myers-Squibb, AbbVie
Rennie Mills, PA-C
Organizer
Advisory Board: Gilead
Minhhuyen Nguyen, MD
Organizer
Nothing to disclose
Norah Terrault, MD
Organizer, Faculty
Consulting: Dynavax Technologies, Novartis Pharmaceuticals, Echosens North America Inc
Continuing Medical Education: Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc
Educational Material Development: CCO Hepatitis
John Ward, MD
Organizer
Nothing to disclose
Stephanie Graham, MA
AASLD Staff
Nothing to disclose
Claudia Ventura
AASLD Staff
Nothing to disclose
Online Learning Committee
Calvin Q. Pan, MD, MACP, FAASLD
Reviewer
Advisory Board: BMS, Gilead, Abbvie Grants/Research Support: Gilead, Merck Speakers Bureau: BMS, Gilead, Abbvie, salix, Synergy
Lopa Mishra, MD, FAASLD
Reviewer
Nothing to Disclose
Gene Y Im, MD
Reviewer
Nothing to Disclose
Iris W Liou, MD
Reviewer
Nothing to Disclose
Jesse M Civan, MD
Reviewer
Education: Merck
HoChong Gilles, FNP
Reviewer
Nothing to Disclose
Julius Wilder, MD, PhD
Reviewer
Nothing to Disclose
Nicolas M Intagliata, MD
Reviewer
Consulting: Vital Therapies Grants/Research Support: Vital Therapies, Eisai, Sequana Medical
Andrew S. deLemos, MD
Reviewer
Consulting: Novartis
Samar H. Ibrahim, MBCHB
Reviewer
Nothing to Disclose
This enduring material may contain discussion of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference of an unlabeled or investigational use.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Acknowledgement of Commercial Support:
No commercial support was received for this enduring material activity.
